CD82 palmitoylation site mutations could not affect the expression or localization of c-Met, indicating that CD82 regulation of c-Met in tumor cells requires the participation of other post-translational modifications or the assistance of other signaling molecules, which needs to be studied in the future. This evidence concerns the gene CD82 and neoplasm.